<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of allergic contact dermatitis in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of allergic contact dermatitis in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of allergic contact dermatitis in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce A Brod, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph Fowler, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H6508771">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allergic contact dermatitis (ACD) is commonly encountered by the practicing clinician. The most common clinical expression is an eczematous dermatitis that can be mild to severe, acute and short lived or chronic. The management of ACD is based upon the identification of the offending allergen, avoidance of exposure, use of safe alternatives, and treatment of symptoms.
        </p>
        <p>
         This topic will discuss the management of ACD. The basic mechanisms, clinical manifestations, and diagnosis of ACD; common allergens in ACD; and patch testing are discussed separately. Poison ivy dermatitis, eyelid dermatitis, hand eczema, and contact dermatitis in children are also discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13653.html" rel="external">
          "Basic mechanisms and pathophysiology of allergic contact dermatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">
          "Clinical features and diagnosis of allergic contact dermatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">
          "Common allergens in allergic contact dermatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">
          "Patch testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1728.html" rel="external">
          "Poison ivy (
          <i>
           Toxicodendron
          </i>
          ) dermatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/120320.html" rel="external">
          "Eyelid dermatitis (eczema)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13658.html" rel="external">
          "Chronic hand eczema"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1731.html" rel="external">
          "Allergic contact dermatitis in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6233164">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal management of ACD requires a multipronged approach [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identification and avoidance of the offending allergen
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alternatives to offending products
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin protection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of skin inflammation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restoration of the skin barrier
        </p>
        <p>
        </p>
        <p>
         The identification of the offending allergen is a key step in the management of ACD. Although the offending allergen is often identified through a detailed history, patch testing may be necessary to identify specific antigens. (See
         <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">
          "Clinical features and diagnosis of allergic contact dermatitis", section on 'History'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">
          "Patch testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6508906">
         <span class="h1">
          ALLERGEN AVOIDANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The education of patients on avoidance of offending substances and recommendations of alternative, allergen-free products are a critical part of the management of patients with ACD [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1455371476">
         <span class="h2">
          Patient education
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is helpful to provide patients with information to help them understand the complex nature of their dermatitis and implement appropriate allergen avoidance and skin protection measures. Information for patients can be found on the websites of most of the companies that manufacture the allergens used for patch testing or systems to detect allergens (eg, specific metals) in commonly used objects, including SmartPractice (www.truetest.com and www.allergeaze.com), Chemotechnique Diagnostics (www.chemotechnique.se), the Contact Dermatitis Institute (www.contactdermatitisinstitute.com), as well as the American Contact Dermatitis Society
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.contactderm.org%2Fpatient-support%2Fallergen-information&amp;token=V5gJoYfhF0RV83VAjuVvalll8PzDmWxOt2QVxb7HGiQtR7s%2BuYqUCBzVIL1sttT7SFv1KKk9wA0MPLExmPaIQeumHEtMrdmUOEJifiQxEps%3D&amp;TOPIC_ID=13665" target="_blank">
          website
         </a>
         .
        </p>
        <p class="headingAnchor" id="H75408236">
         <span class="h2">
          Common contact allergens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Common contact allergens include plant allergens, metals, fragrances, acrylates, medicaments, and preservatives.
        </p>
        <p class="headingAnchor" id="H75408200">
         <span class="h3">
          Plants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many plant families that are ubiquitous throughout the world, including Anacardiaceae (eg,
         <em>
          Toxicodendron
         </em>
         [poison ivy], cashew nut tree, Indian marking nut tree, mango tree), Compositae (eg, ragweed, goldenrod, sunflowers, chamomile, chrysanthemums), Alliaceae (eg, garlic, onion), and Myrtaceae (eg, tea tree), contain resins and oils that can cause ACD in sensitized individuals [
         <a href="#rid3">
          3,4
         </a>
         ]. Compositae and Anacardiaceae are also responsible for most cases of airborne ACD, due to exposure to pollen or other particles suspended in the air.
        </p>
        <p>
         The avoidance measures for contact allergy to plants of the
         <em>
          Toxicodendron
         </em>
         genus (poison ivy, oak, and sumac) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1728.html" rel="external">
          "Poison ivy (
          <i>
           Toxicodendron
          </i>
          ) dermatitis", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H75408207">
         <span class="h3">
          Nickel
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nickel is found in alloys and plated objects, including jewelry, buttons, zippers, coins, keys, scissors, children's toys [
         <a href="#rid5">
          5
         </a>
         ], cell phones [
         <a href="#rid6">
          6
         </a>
         ], handheld computers [
         <a href="#rid7">
          7
         </a>
         ], and metal tools. (See
         <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">
          "Common allergens in allergic contact dermatitis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Identifying nickel in common use objects
         </strong>
         – Providing patients who are nickel sensitive with a list of objects that may contain nickel may be helpful. A nickel test kit may also be useful for patients to identify nickel-releasing objects at home or at work. These kits, which use dimethylglyoxime, do not harm the object being tested. In one study, the nickel spot test had a sensitivity and specificity of 60 and 98 percent, respectively, in detecting nickel released in amounts &gt;0.5 microg/cm
         <sup>
          2
         </sup>
         per week by a set of earrings [
         <a href="#rid8">
          8
         </a>
         ]. This is the threshold established by the European Union Nickel Directive for products intended to be in direct and prolonged contact with the skin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoiding nickel exposure
         </strong>
         – Since jewelry (including some yellow and white gold jewelry) and metal components of clothing are the most common sources of nickel that are in prolonged contact with the skin, several avoidance measures have been suggested to limit nickel exposure from these sources [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Coating a nickel object with a physical barrier may prevent the release of nickel ions. The application of a clear barrier (eg, Nickel Guard) or clear nail polish to the buttons and rivets of jeans may prevent nickel release through at least two wash and dry cycles [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Iron-on patches may be applied on clothes to cover metal parts that come in contact with the skin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Duct tape can adhere to the inside of buttons or snaps; it is inexpensive, easy to apply, and widely available.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chemical barriers for nickel include chelating and nonchelating barrier creams. Barrier creams containing agents such as disodium ethylenediaminetetraacetate (EDTA) act by chelating the positive ionic charge and rendering the metal inactive [
         <a href="#rid11">
          11,12
         </a>
         ]. Nonchelating creams may prevent the penetration of nickel through the skin.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H75408214">
         <span class="h3">
          Cosmetics and personal care products
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although cosmetics and personal care products contain a high number of chemical ingredients, only a few of them are responsible for most cases of ACD. These include [
         <a href="#rid13">
          13-16
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">
          "Common allergens in allergic contact dermatitis", section on 'Preservatives'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">
          "Common allergens in allergic contact dermatitis", section on 'Fragrances'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fragrances and botanicals (limonene, linalool)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preservatives (eg, quaternium-15, methylisothiazolinone [MI] or the combination of methylchloroisothiazolinone [MCI]/MI [marketed as Kathon CG or Kathon WT], imidazolidinyl and diazolidinyl urea, and others)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excipients (eg, propylene glycol,
         <a class="drug drug_general" data-topicid="101844" href="/z/d/drug information/101844.html" rel="external">
          lanolin
         </a>
         , or colorants)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glues (eg, acrylates in nail products)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sunscreens
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hair dyes (para-phenylenediamine and derivatives)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surfactants (cocamidopropyl
         <a class="drug drug_general" data-topicid="8598" href="/z/d/drug information/8598.html" rel="external">
          betaine
         </a>
         , decyl glucosides)
        </p>
        <p>
        </p>
        <p>
         Learning to read the labels of cosmetic or personal care products is important for patients with ACD. Information on specific ingredients in personal care or household products commercialized in the United States can be found online at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.whatsinproducts.com%2F&amp;token=mr3MkQMxxRm373pPGLTYB1lEaJ5jhQOx4rI39GBMuJ%2BFSXmrcn8%2BfSTFYX%2FM6FMG&amp;TOPIC_ID=13665" target="_blank">
          Consumer Product Information Database
         </a>
         .
        </p>
        <p class="headingAnchor" id="H6233243">
         <span class="h2">
          Alternative products
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians may obtain information on alternative products for patients with allergies from several sources. The Contact Allergen Management Program of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.contactderm.org%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlJeM9y1O0p73moz91QGTAZzYc8WIXgNyCf5o%2FdoU1sQ%2F&amp;TOPIC_ID=13665" target="_blank">
          American Contact Dermatitis Society
         </a>
         , which requires membership, allows the clinician to create an individualized list of products, including gloves that are free of specific allergens. SkinSAFE is another resource for alternative products [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         The American Contact Alternatives Group provides an extensive list of alternatives for the allergens included in the 2018 American Contact Dermatitis Society core series [
         <a href="#rid18">
          18
         </a>
         ]. Specific lists of alternatives for facial cosmetics and hair products containing few or none of the allergens included in the core allergen series of the American Contact Dermatitis Society are also available [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26565598">
         <span class="h1">
          ALLERGEN AVOIDANCE AND ALLERGIC CONTACT DERMATITIS PREVENTION IN THE WORKPLACE
         </span>
        </p>
        <p class="headingAnchor" id="H3890128311">
         <span class="h2">
          General measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avoidance in the workplace requires a more complex strategy. Several general measures may be adopted in the workplace to reduce exposure to chemicals, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Substitution of safer alternatives for allergenic materials
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Automation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Process enclosure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of equipment for handling substances [
         <a href="#rid21">
          21
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Keeping a safe working distance
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Promptly washing any chemical exposures from the skin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using protective clothing and gloves
        </p>
        <p>
        </p>
        <p>
         Occupational prevention measures include [
         <a href="#rid22">
          22
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Workplace training programs focused on barrier repair, hazards of wet work
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regular examinations for early disease recognition
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Capacity to manage more advanced disease
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2584634358">
         <span class="h2">
          Protective gloves
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protective gloves can reduce or eliminate the exposure of the hands to hazardous substances. Gloves are ideally selected based on the glove permeation and degradation properties and the nature of the compounds that are manipulated [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Multilayer laminate gloves, which incorporate a hydrophilic/polar layer between two hydrophobic/nonpolar layers, usually provide a high level of protection against a wide range of chemicals. Manufacturers of protective gloves provide lists of applications, hazards, and chemicals for which their gloves have been tested (eg, www.bestglove.com or www.ansell.com).
        </p>
        <p>
         However, gloves (particularly rubber gloves) contain allergens that may worsen hand dermatitis in some patients. Also, improperly chosen gloves may actually allow allergen penetration and then trap the allergen against the skin. Education on the proper way to put on and take off gloves is required to minimize exposures.
        </p>
        <p class="headingAnchor" id="H320147">
         <span class="h2">
          Skin protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Irritant contact dermatitis is often associated with or precedes the development of ACD. Prework (barrier) creams and after work (emollient) creams appear to confer some degree of protection against irritant contact dermatitis, although evidence from randomized trials is limited [
         <a href="#rid24">
          24
         </a>
         ]. The substitution of milder detergents for abrasive or irritating cleansers and the application of allergen-free emollients (eg, petrolatum-based emollients) after each hand washing may reduce the risk of hand dermatitis at the workplace [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         The regular application of emollients to normal skin after repeated exposure to irritants may help to maintain the skin barrier function [
         <a href="#rid26">
          26
         </a>
         ]. Emollients may be liberally used as an adjunct to corticosteroids in the treatment of ACD, particularly chronic, lichenified dermatitis.
        </p>
        <p class="headingAnchor" id="H6508920">
         <span class="h1">
          PHARMACOLOGIC TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although avoidance of the offending allergen is the mainstay of management of ACD, pharmacologic treatment is required to achieve rapid control of symptoms in most cases. The treatment of ACD follows the general principles of eczema treatment and includes topical corticosteroids and topical calcineurin inhibitors, systemic immunosuppressors, and phototherapy. Emollients may be liberally used as an adjunct to corticosteroids in the treatment of ACD, particularly chronic, lichenified dermatitis.
        </p>
        <p>
         The approach to treatment depends on the severity of ACD and the site(s) involved  (
         <a class="graphic graphic_algorithm graphicRef140103" href="/z/d/graphic/140103.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid16">
          16,25,27-32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3820365022">
         <span class="h2">
          Acute, localized allergic contact dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical corticosteroids and topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         are first-line treatments for acute, localized ACD. Emollients can be liberally used multiple times per day as an adjunctive treatment to topical therapy.
        </p>
        <p class="headingAnchor" id="H2061126073">
         <span class="h3">
          Hands, feet, and nonflexural areas
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest high-potency topical corticosteroids (groups 1 to 3  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) for treatment of ACD that does not involve the face or flexural areas  (
         <a class="graphic graphic_algorithm graphicRef140103" href="/z/d/graphic/140103.html" rel="external">
          algorithm 1
         </a>
         ). Topical corticosteroids are applied once or twice daily for two to four weeks or until resolution of symptoms. If the dermatitis is acute and weeping, topical corticosteroids may be used in combination with drying agents (eg,
         <a class="drug drug_general" data-topicid="95641" href="/z/d/drug information/95641.html" rel="external">
          aluminum acetate
         </a>
         compresses,
         <a class="drug drug_general" data-topicid="16451" href="/z/d/drug information/16451.html" rel="external">
          calamine lotion
         </a>
         , colloidal oatmeal compresses or baths).
        </p>
        <p>
         Potential adverse effects of topical corticosteroids include cutaneous atrophy, telangiectasias, and striae. They are more likely to occur with prolonged use of high-potency agents and especially on facial and intertriginous skin. (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects"
         </a>
         .)
        </p>
        <p>
         The efficacy of topical corticosteroids for the treatment of ACD has been evaluated in a few small, randomized trials, some of which were performed in individuals with experimentally induced ACD [
         <a href="#rid33">
          33-36
         </a>
         ]. However, their use is largely supported by evidence for efficacy in other forms of eczematous dermatitis [
         <a href="#rid27">
          27,37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3627790073">
         <span class="h3">
          Face and flexural areas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the management of acute ACD involving the face and/or flexural areas is as follows  (
         <a class="graphic graphic_algorithm graphicRef140103" href="/z/d/graphic/140103.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest medium- to low-potency topical corticosteroids (groups 4 to 6  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) as the initial treatment for mild to moderate ACD of the face and flexural areas. Topical corticosteroids are applied once or twice daily for one to two weeks. Thereafter, topical corticosteroids can be tapered (eg, with every other day application) over the following two weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         is an alternative to topical corticosteroids for patients who require prolonged, continuous treatment (beyond two weeks). Unlike topical corticosteroids, topical calcineurin inhibitors do not cause skin atrophy. Tacrolimus 0.1% ointment is applied twice daily until improvement is noted and then tapered. Local adverse effects of topical calcineurin inhibitors include burning and stinging at the site of application.
        </p>
        <p>
        </p>
        <p>
         The efficacy of topical calcineurin inhibitors for ACD has been evaluated in a few small, randomized trials, some of which involving individuals with experimentally induced ACD [
         <a href="#rid28">
          28,29,35,36,38
         </a>
         ]. In one study,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         0.1% ointment applied twice daily was more effective than placebo in clearing the eruption over eight weeks of continued exposure to the allergen [
         <a href="#rid28">
          28
         </a>
         ].
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          Pimecrolimus
         </a>
         1% cream does not seem to be effective for ACD [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         There are no high-quality studies comparing topical calcineurin inhibitors with topical corticosteroids for the treatment of ACD. In a small trial that involved 30 patients with chronic hand ACD,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         0.1% ointment was as effective as
         <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">
          mometasone
         </a>
         furoate 0.1% ointment in reducing erythema, infiltration, vesiculation, desquamation, and itching [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1681546722">
         <span class="h2">
          Extensive, severe, or disabling allergic contact dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest systemic corticosteroids as the first-line treatment for acute extensive, severe, or disabling ACD (ie, involving &gt;20 percent of the total body surface area or involving the face, hands, feet, or genitalia)  (
         <a class="graphic graphic_algorithm graphicRef140103" href="/z/d/graphic/140103.html" rel="external">
          algorithm 1
         </a>
         ). Treatment is started with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or equivalent dose of other systemic corticosteroids  (
         <a class="graphic graphic_table graphicRef64138" href="/z/d/graphic/64138.html" rel="external">
          table 2
         </a>
         )) at a dose of 0.5 to 1 mg/kg per day (maximum 60 mg/day) for seven days. The dose may be reduced by 50 percent over the next five to seven days and then tapered and discontinued over the following two weeks.
        </p>
        <p>
         Systemic corticosteroids for ACD have not been studied in randomized trials. In clinical practice, they are frequently beneficial in the treatment of poison ivy dermatitis, a common form of ACD. (See
         <a class="medical medical_review" href="/z/d/html/1728.html" rel="external">
          "Poison ivy (
          <i>
           Toxicodendron
          </i>
          ) dermatitis", section on 'Severe dermatitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1039422539">
         <span class="h2">
          Chronic allergic contact dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breakdown of the skin barrier (atrophy) is a complicating factor in many cases of chronic ACD and is exacerbated by overuse of topical corticosteroids. Every effort should be made to minimize continuous use of these agents beyond two to four weeks.
        </p>
        <p>
         Allergen-free emollients may be liberally used as an adjunct to active topical therapies in the treatment of ACD, particularly chronic, lichenified dermatitis  (
         <a class="graphic graphic_algorithm graphicRef140103" href="/z/d/graphic/140103.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermittent topical corticosteroids
         </strong>
         – We suggest intermittent high-potency topical corticosteroids (groups 1
         <strong>
         </strong>
         to 3  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) for long-term control of chronic ACD involving the hands, feet, or nonflexural areas. Topical corticosteroids are applied once daily for 7 to 10 days initially, followed by every-other-day treatment. In case of recurrence, continuous treatment can be reinstated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a randomized trial, 120 patients with chronic hand eczema initially treated with
         <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">
          mometasone
         </a>
         furoate 0.1% fatty cream for up to nine weeks or until the dermatitis cleared were randomly assigned to a 30-week maintenance period with intermittent mometasone furoate (once daily on Sunday, Tuesday, and Thursday or on Saturday and Sunday) or vehicle. Mometasone furoate applied three times weekly was more effective than vehicle in preventing recurrence of dermatitis (83 versus 26 percent) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical
         </strong>
         <strong>
          tacrolimus
         </strong>
         – We suggest topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         for the management of chronic ACD localized to the face or intertriginous areas and for chronic, localized ACD resistant to topical corticosteroids. Tacrolimus 0.1% ointment can be applied once or twice daily to affected areas until resolution. Treatment can be restarted if there is a recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second-line therapies
         </strong>
         – For patients with chronic ACD that is unresponsive to topical therapies, therapeutic options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Phototherapy
         </strong>
         – Small, observational studies of patients with chronic hand eczema of various etiologies demonstrated clinical improvement with bath psoralen plus ultraviolet A (PUVA) photochemotherapy or narrowband ultraviolet B (NBUVB) [
         <a href="#rid30">
          30-32,40
         </a>
         ]. NBUVB is more convenient for the patient and associated with fewer side effects than PUVA. (See
         <a class="medical medical_review" href="/z/d/html/13658.html" rel="external">
          "Chronic hand eczema"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">
          "Psoralen plus ultraviolet A (PUVA) photochemotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">
          "UVB phototherapy (broadband and narrowband)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Systemic immunosuppressive agents
         </strong>
         –
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil, and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         are infrequently used for the management of chronic ACD [
         <a href="#rid41">
          41
         </a>
         ]. Situations such as airborne plant contact dermatitis from Compositae (eg, parthenium, ragweed, aster, sunflower, chrysanthemum, artichoke) or photodermatitis, where allergen avoidance is impossible, are examples.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H497536588">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no reliable method to desensitize patients to allergens. The prognosis for improvement hinges on the ability to avoid allergen(s) and, if applicable, their cross-reacting substances [
         <a href="#rid2">
          2
         </a>
         ]. Allergens that are more ubiquitous in the environment, such as sesquiterpene lactones found in common outdoor plants or formaldehyde commonly found in the workplace and household products, tend to be associated with a less favorable prognosis. Outcomes related to occupational contact dermatitis depend on the ability to establish a workplace free of allergens.
        </p>
        <p class="headingAnchor" id="H880366424">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113033.html" rel="external">
          "Society guideline links: Contact dermatitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H320159">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergen avoidance
         </strong>
         –
         <strong>
         </strong>
         Allergen
         <strong>
         </strong>
         avoidance is the cornerstone of the management of allergic contact dermatitis (ACD). Educating patients about avoidance of offending substances and use of alternative, allergen-free products is a critical part of the management of ACD. Avoiding occupational exposures requires a complex strategy that may involve engineering control methods (eg, automation, process enclosure), personal hygiene measures (eg, promptly washing chemicals from the skin), and using personal protective equipment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Information for patients can be found on the websites of most companies that manufacture allergens used for patch testing or systems to identify allergens in commonly used objects (eg, www.smartpractice.com, www.truetest.com, www.allergeaze.com, www.chemotechnique.se) as well as the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.contactderm.org%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlJeM9y1O0p73moz91QGTAZzYc8WIXgNyCf5o%2FdoU1sQ%2F&amp;TOPIC_ID=13665" target="_blank">
          American Contact Dermatitis Society
         </a>
         website. (See
         <a class="local">
          'Allergen avoidance'
         </a>
         above and
         <a class="local">
          'Allergen avoidance and allergic contact dermatitis prevention in the workplace'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin protection
         </strong>
         – Prework (barrier) creams and after work (emollient) creams appear to confer some degree of protection against contact dermatitis, although evidence from randomized trials is limited. Regular use of emollients may help to maintain the skin barrier function. (See
         <a class="local">
          'Skin protection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacologic treatment
         </strong>
         – The approach to treatment depends on the severity of ACD and the site(s) involved  (
         <a class="graphic graphic_algorithm graphicRef140103" href="/z/d/graphic/140103.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Pharmacologic treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute, limited allergic contact dermatitis of the hands, feet, and nonintertriginous areas
         </strong>
         – We suggest high-potency topical corticosteroids (groups 1 to 3  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) for the treatment of ACD that involves &lt;20 percent of the body surface area, does not involve the face or flexural areas, and is not disabling (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Topical corticosteroids are applied once or twice daily for two to four weeks or until resolution of symptoms. (See
         <a class="local">
          'Hands, feet, and nonflexural areas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute, localized allergic contact dermatitis of the face and intertriginous areas
         </strong>
         – We suggest medium- to low-potency topical corticosteroids (groups 4 to 6  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) rather than topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         as initial therapy for mild to moderate ACD of the face and flexural areas (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Topical corticosteroids are applied once or twice daily for one to two weeks. Topical tacrolimus is a reasonable alternative for patients who require prolonged, continuous treatment (beyond two weeks). Topical tacrolimus 0.1% ointment is applied twice daily until resolution and then tapered. (See
         <a class="local">
          'Face and flexural areas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extensive, severe, or disabling allergic contact dermatitis
         </strong>
         – We suggest systemic, rather than topical, corticosteroids as the first-line treatment for acute extensive, severe, or disabling ACD (ie, involving &gt;20 percent of the total body surface area or involving the face, hands, feet, or genitalia) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Treatment is started with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or equivalent dose of other systemic corticosteroids  (
         <a class="graphic graphic_table graphicRef64138" href="/z/d/graphic/64138.html" rel="external">
          table 2
         </a>
         )) at a dose of 0.5 to 1 mg/kg per day (maximum 60 mg per day) for seven days. The dose may be reduced by 50 percent in the next five to seven days and then tapered and discontinued over the following two weeks. (See
         <a class="local">
          'Extensive, severe, or disabling allergic contact dermatitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chronic allergic contact dermatitis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Hands, feet, nonflexural areas
         </strong>
         – For long-term control of chronic ACD involving the hands, feet, or nonflexural areas, we suggest
         <strong>
          intermittent
         </strong>
         high-potency topical corticosteroids (groups 1 to 3  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) rather than continuous treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Topical corticosteroids are applied once daily three times per week on alternate days.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Face and flexural areas
         </strong>
         – For chronic ACD of the face and flexural areas, we suggest topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         over topical corticosteroids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Topical tacrolimus 0.1% ointment is applied once or twice daily for as long as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Refractory, chronic allergic contact dermatitis
         </strong>
         – Phototherapy with psoralen plus ultraviolet A (PUVA) or narrowband ultraviolet B (NBUVB) or systemic immunosuppressive medications are therapeutic options in patients with chronic ACD that is unresponsive to topical or oral corticosteroids. (See
         <a class="local">
          'Chronic allergic contact dermatitis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bikowski JB. Hand eczema: diagnosis and management. Cutis 2008; 82:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mowad CM, Anderson B, Scheinman P, et al. Allergic contact dermatitis: Patient management and education. J Am Acad Dermatol 2016; 74:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheehan MP. Plant Associated Irritant &amp; Allergic Contact Dermatitis (Phytodermatitis). Dermatol Clin 2020; 38:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schloemer JA, Zirwas MJ, Burkhart CG. Airborne contact dermatitis: common causes in the USA. Int J Dermatol 2015; 54:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen P, Hamann D, Hamann CR, et al. Nickel and cobalt release from children's toys purchased in Denmark and the United States. Dermatitis 2014; 25:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen P, Johansen JD, Zachariae C, et al. Excessive nickel release from mobile phones--a persistent cause of nickel allergy and dermatitis. Contact Dermatitis 2011; 65:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob SE, Admani S. iPad--increasing nickel exposure in children. Pediatrics 2014; 134:e580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thyssen JP, Skare L, Lundgren L, et al. Sensitivity and specificity of the nickel spot (dimethylglyoxime) test. Contact Dermatitis 2010; 62:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu LK, Warshaw EM, Dunnick CA. Prevention of nickel allergy: the case for regulation? Dermatol Clin 2009; 27:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suneja T, Flanagan KH, Glaser DA. Blue-jean button nickel: prevalence and prevention of its release from buttons. Dermatitis 2007; 18:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Ketel WG, Bruynzeel DP. Chelating effect of EDTA on nickel. Contact Dermatitis 1984; 11:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wöhrl S, Kriechbaumer N, Hemmer W, et al. A cream containing the chelator DTPA (diethylenetriaminepenta-acetic acid) can prevent contact allergic reactions to metals. Contact Dermatitis 2001; 44:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madsen JT, Andersen KE. Further evidence of the methylisothiazolinone epidemic. Contact Dermatitis 2014; 70:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loranger C, Alfalah M, Ferrier Le Bouedec MC, Sasseville D. Alkyl Glucosides in Contact Dermatitis. Dermatitis 2017; 28:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonacier L, Bernstein DI, Pacheco K, et al. Contact dermatitis: a practice parameter-update 2015. J Allergy Clin Immunol Pract 2015; 3:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology. Contact dermatitis: a practice parameter. Ann Allergy Asthma Immunol 2006; 97:S1.
          </a>
         </li>
         <li class="breakAll">
          www.skinsafeproducts.com/ (Accessed on February 27, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheman A, Hylwa-Deufel S, Jacob SE, et al. Alternatives for Allergens in the 2018 American Contact Dermatitis Society Core Series: Report by the American Contact Alternatives Group. Dermatitis 2019; 30:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheman A, Jacob S, Katta R, et al. Part 1 of a 4-part series Facial Cosmetics: Trends and Alternatives: Data from the American Contact Alternatives Group. J Clin Aesthet Dermatol 2011; 4:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheman A, Jacob S, Katta R, et al. Part 2 of a 4-part series Hair Products: Trends and Alternatives: Data from the American Contact Alternatives Group. J Clin Aesthet Dermatol 2011; 4:42.
          </a>
         </li>
         <li class="breakAll">
          Forsberg K, Van den Borre A, Henry N, et al. Quick Selection Guide to Chemical Protective Clothing, 6th ed, John Wiley and Sons, 2014.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zack B, Arrandale VH, Holness DL. Preventing Occupational Skin Disease: A Review of Training Programs. Dermatitis 2017; 28:169.
          </a>
         </li>
         <li class="breakAll">
          University of California Berkeley: Office of Environment, Health &amp; Safety. Glove Selection Guide. https://ehs.berkeley.edu/glove-selection-guide (Accessed on March 29, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer A, Schmitt J, Bennett C, et al. Interventions for preventing occupational irritant hand dermatitis. Cochrane Database Syst Rev 2010; :CD004414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke J, Coulson I, English J, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of contact dermatitis: an update. Br J Dermatol 2009; 160:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams C, Wilkinson SM, McShane P, et al. A double-blind, randomized study to assess the effectiveness of different moisturizers in preventing dermatitis induced by hand washing to simulate healthcare use. Br J Dermatol 2010; 162:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belsito D, Wilson DC, Warshaw E, et al. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol 2006; 55:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacor ML, Di Lorenzo G, Martinelli N, et al. Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc 2006; 27:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schempp CM, Müller H, Czech W, et al. Treatment of chronic palmoplantar eczema with local bath-PUVA therapy. J Am Acad Dermatol 1997; 36:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Coevorden AM, Kamphof WG, van Sonderen E, et al. Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy. Arch Dermatol 2004; 140:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed 2007; 23:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grandolfo M, Vena GA, Angelini G, Bianchi B. Mometasone furoate versus betamethasone vale-rate in the treatment of allergic contact dermatitis. J Eur Acad Dermatol Venereol 1999; 12:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hachem JP, De Paepe K, Vanpée E, et al. Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol 2002; 27:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhardwaj SS, Jaimes JP, Liu A, Warshaw EM. A double-blind randomized placebo-controlled pilot study comparing topical immunomodulating agents and corticosteroids for treatment of experimentally induced nickel contact dermatitis. Dermatitis 2007; 18:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katsarou A, Makris M, Papagiannaki K, et al. Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol 2012; 22:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broeders JA, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. J Am Acad Dermatol 2016; 75:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mose KF, Andersen F, Røpke MA, et al. Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone. Br J Clin Pharmacol 2018; 84:1719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veien NK, Olholm Larsen P, Thestrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol 1999; 140:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen L, Stensgaard A, Andersen KE. Psoralen plus ultraviolet A (PUVA) soaks and UVB TL01 treatment for chronic hand dermatoses. Dermatol Reports 2012; 4:e3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung CT, McGowan MA, Machler BC, Jacob SE. Systemic Treatments for Allergic Contact Dermatitis. Dermatitis 2019; 30:46.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13665 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19202671" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hand eczema: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27185422" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Allergic contact dermatitis: Patient management and education.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32475517" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Plant Associated Irritant&amp;Allergic Contact Dermatitis (Phytodermatitis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24981079" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Airborne contact dermatitis: common causes in the USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25384229" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Nickel and cobalt release from children's toys purchased in Denmark and the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22077435" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Excessive nickel release from mobile phones--a persistent cause of nickel allergy and dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25022741" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : iPad--increasing nickel exposure in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20536475" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Sensitivity and specificity of the nickel spot (dimethylglyoxime) test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19254659" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prevention of nickel allergy: the case for regulation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18021600" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Blue-jean button nickel: prevalence and prevention of its release from buttons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6441675" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Chelating effect of EDTA on nickel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11260238" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A cream containing the chelator DTPA (diethylenetriaminepenta-acetic acid) can prevent contact allergic reactions to metals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24628350" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Further evidence of the methylisothiazolinone epidemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27775979" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Alkyl Glucosides in Contact Dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25965350" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Contact dermatitis: a practice parameter-update 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17039663" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Contact dermatitis: a practice parameter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17039663" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Contact dermatitis: a practice parameter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30870231" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Alternatives for Allergens in the 2018 American Contact Dermatitis Society Core Series: Report by the American Contact Alternatives Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21779413" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Part 1 of a 4-part series Facial Cosmetics: Trends and Alternatives: Data from the American Contact Alternatives Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21779419" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Part 2 of a 4-part series Hair Products: Trends and Alternatives: Data from the American Contact Alternatives Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21779419" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Part 2 of a 4-part series Hair Products: Trends and Alternatives: Data from the American Contact Alternatives Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28509714" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Preventing Occupational Skin Disease: A Review of Training Programs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28509714" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Preventing Occupational Skin Disease: A Review of Training Programs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20556758" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Interventions for preventing occupational irritant hand dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19302065" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Guidelines for the management of contact dermatitis: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20199550" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A double-blind, randomized study to assess the effectiveness of different moisturizers in preventing dermatitis induced by hand washing to simulate healthcare use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134919" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Systematic review of treatments for atopic eczema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16781290" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17176790" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9146535" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Treatment of chronic palmoplantar eczema with local bath-PUVA therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15611423" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17254029" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10343953" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mometasone furoate versus betamethasone vale-rate in the treatment of allergic contact dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11952670" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy of topical corticosteroids in nickel-induced contact allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17303041" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A double-blind randomized placebo-controlled pilot study comparing topical immunomodulating agents and corticosteroids for treatment of experimentally induced nickel contact dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22407003" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27177441" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29607554" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10354026" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Long-term, intermittent treatment of chronic hand eczema with mometasone furoate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25386313" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Psoralen plus ultraviolet A (PUVA) soaks and UVB TL01 treatment for chronic hand dermatoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30570582" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Systemic Treatments for Allergic Contact Dermatitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
